- Home
- EDIT vs RCEL Comparison
EDIT vs RCEL Comparison
Compare EDIT & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDIT
- RCEL
- Stock Information
- Founded
- EDIT 2013
- RCEL N/A
- Country
- EDIT United States
- RCEL United States
- Employees
- EDIT N/A
- RCEL N/A
- Industry
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- RCEL Medical/Dental Instruments
- Sector
- EDIT Health Care
- RCEL Health Care
- Exchange
- EDIT Nasdaq
- RCEL Nasdaq
- Market Cap
- EDIT 156.5M
- RCEL 161.5M
- IPO Year
- EDIT 2016
- RCEL N/A
- Fundamental
- Price
- EDIT $2.25
- RCEL $5.19
- Analyst Decision
- EDIT Buy
- RCEL Strong Buy
- Analyst Count
- EDIT 13
- RCEL 4
- Target Price
- EDIT $6.73
- RCEL $16.50
- AVG Volume (30 Days)
- EDIT 2.4M
- RCEL 287.8K
- Earning Date
- EDIT 08-06-2025
- RCEL 08-07-2025
- Dividend Yield
- EDIT N/A
- RCEL N/A
- EPS Growth
- EDIT N/A
- RCEL N/A
- EPS
- EDIT N/A
- RCEL N/A
- Revenue
- EDIT $35,837,000.00
- RCEL $71,661,000.00
- Revenue This Year
- EDIT N/A
- RCEL $57.29
- Revenue Next Year
- EDIT N/A
- RCEL $28.07
- P/E Ratio
- EDIT N/A
- RCEL N/A
- Revenue Growth
- EDIT N/A
- RCEL 41.35
- 52 Week Low
- EDIT $0.91
- RCEL $5.10
- 52 Week High
- EDIT $6.05
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- EDIT 63.76
- RCEL 29.07
- Support Level
- EDIT $2.05
- RCEL $5.10
- Resistance Level
- EDIT $2.55
- RCEL $6.33
- Average True Range (ATR)
- EDIT 0.23
- RCEL 0.32
- MACD
- EDIT 0.03
- RCEL 0.02
- Stochastic Oscillator
- EDIT 66.29
- RCEL 6.10
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.